MASH
Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor
Inventiva, layoffs, pipeline reduction, lanifibranor, MASH, Phase 3 trial, biotech restructuring
Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships
Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations
Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies
Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment
Akero Therapeutics Stock Skyrockets as Phase 2b MASH Trial Yields Groundbreaking Results
Akero Therapeutics, MASH, Efruxifermin, Phase 2b SYMMETRY Study, Stock Price, Transformational Data
Belapectin Shows Promising Reduction in Esophageal Varices in MASH Cirrhosis Patients, Despite Missing Primary Endpoint
Belapectin, MASH Cirrhosis, Portal Hypertension, Esophageal Varices, Clinical Trial, Galectin Therapeutics
Boston Pharmaceuticals Achieves Phase 2 Success with Efimosfermin Alfa for MASH Treatment, Paving Way for Pivotal Trials
Efimosfermin alfa (BOS-580), Metabolic dysfunction-associated steatohepatitis (MASH), Non-alcoholic steatohepatitis (NASH), Phase 2 clinical trials, FGF21 analogue, Liver disease treatment, Pivotal trials
Novo Nordisk’s Wegovy Shows Superior Improvement in Liver Fibrosis and MASH Resolution in Phase III ESSENCE Trial
Novo Nordisk, Wegovy, semaglutide, MASH, liver fibrosis, Phase III ESSENCE trial, Madrigal Pharmaceuticals, Rezdiffra
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical
Aligos Therapeutics Reports Positive Phase IIa Results for MASH Treatment, Despite Investor Skepticism
Aligos Therapeutics, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase IIa trial, ALG-055009, Liver fat reduction, Investor skepticism, Placebo effect
Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors
Aligos Therapeutics, HERALD study, MASH treatment, ALG-055009, liver fat reduction, Phase 2a results, investor reaction.